Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine S Panageas

Showing results (1-10 of 280) with videos related to

Pageof 28
Sort By:
Expert Review of Clinical Pharmacology|October 31, 2015
Clinical trial design for rare cancers: why a less conventional route may be requiredKatherine S Panageas
Journal of Hospital Management and Health Policy|July 16, 2019
Appropriate statistical methods are available to handle biases encountered in blinded, independent, central review (BICR) determined progression-free survivalJessica A Lavery, Katherine S Panageas
Journal of Neurosurgery|June 4, 2016
Letter to the Editor: Biases in estimation of overall survival in patients who underwent repeat resection of glioblastomaDebra A Goldman, Katherine S Panageas
JACC. Cardiooncology|August 16, 2021
Cancer and Clot: A Deadly DanceKatherine S Panageas, Lisa M DeAngelis
JNCI Cancer Spectrum|November 10, 2022
Kaposi Sarcoma in the United States: Understanding Disparate RiskAnne S Reiner, Katherine S Panageas
JAMA Oncology|June 20, 2020
Implications for Design and Analyses of Oncology Clinical Trials During the COVID-19 PandemicChaya S Moskowitz, Katherine S Panageas
Statistics in Medicine|January 17, 2003
A statistical perspective on gene expression data analysisJaya M Satagopan, Katherine S Panageas
JCO Oncology Practice|December 17, 2020
Electronic Medical Record Documentation and Provider BurnoutDebra A Goldman, Katherine S Panageas
Leukemia & Lymphoma|December 16, 2006
Identifying and addressing barriers to the delivery of optimal therapy for primary central nervous system lymphoma in the broader communityLauren E Abrey, Katherine S Panageas
JAMA|October 14, 2010
Cancer screening among patients with advanced cancerCamelia S Sima, Katherine S Panageas, Deborah Schrag
Pageof 28

Showing results (1-10 of 280) with videos related to

Sort By:
Pageof 28
Expert Review of Clinical Pharmacology|October 31, 2015
Clinical trial design for rare cancers: why a less conventional route may be requiredKatherine S Panageas
Journal of Hospital Management and Health Policy|July 16, 2019
Appropriate statistical methods are available to handle biases encountered in blinded, independent, central review (BICR) determined progression-free survivalJessica A Lavery, Katherine S Panageas
Journal of Neurosurgery|June 4, 2016
Letter to the Editor: Biases in estimation of overall survival in patients who underwent repeat resection of glioblastomaDebra A Goldman, Katherine S Panageas
JACC. Cardiooncology|August 16, 2021
Cancer and Clot: A Deadly DanceKatherine S Panageas, Lisa M DeAngelis
JNCI Cancer Spectrum|November 10, 2022
Kaposi Sarcoma in the United States: Understanding Disparate RiskAnne S Reiner, Katherine S Panageas
JAMA Oncology|June 20, 2020
Implications for Design and Analyses of Oncology Clinical Trials During the COVID-19 PandemicChaya S Moskowitz, Katherine S Panageas
Statistics in Medicine|January 17, 2003
A statistical perspective on gene expression data analysisJaya M Satagopan, Katherine S Panageas
JCO Oncology Practice|December 17, 2020
Electronic Medical Record Documentation and Provider BurnoutDebra A Goldman, Katherine S Panageas
Leukemia & Lymphoma|December 16, 2006
Identifying and addressing barriers to the delivery of optimal therapy for primary central nervous system lymphoma in the broader communityLauren E Abrey, Katherine S Panageas
JAMA|October 14, 2010
Cancer screening among patients with advanced cancerCamelia S Sima, Katherine S Panageas, Deborah Schrag
Pageof 28